IFNA2 and myeloproliferative neoplasm: As of March 1 st, 2024, 90 patients (15.8% of the treated cohort) of our monocentric OBENE cohort (NCT02897297), which prospectively collects information on MPN patients, received PEG-IFNα2a alone (85.6%) or in combination with another cytoreductive drug (14.4%) (Supplementary Fig. 1).